Quest Diagnostics: Doherty to retire in July 2027

The approved award follows substantially the same terms and conditions as 2026 annual long-term incentive awards for other senior executives.

Rhea-AI Filing Summary

Quest Diagnostics Incorporated announced that Catherine T. Doherty will retire in July 2027. Effective November 1, 2026, she will transition to Executive Vice President, with responsibilities including health systems, the Company’s joint venture with Corewell Health, and Project Nova, a multi-year project to modernize its “Order to Cash” business processes, related information technology infrastructure and enabling technologies.

Her annual base salary remains $650,000, and her annual incentive compensation target remains 80% of base salary under the Senior Management Incentive Plan. The Committee approved an Employee Long-Term Incentive Plan award with a target value of $1,200,000, allocated entirely to restricted stock units, with a grant date of November 3, 2026.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Figures

Annual base salary: $650,000 Annual incentive compensation target: 80% of base salary Equity award target value: $1,200,000 +1 more

4 metrics

Annual base salary $650,000 No change approved in connection with the transition

Annual incentive compensation target 80% of base salary Under the Senior Management Incentive Plan

Equity award target value $1,200,000 Employee Long-Term Incentive Plan award

Restricted stock unit allocation 100% Allocation of the equity award

Key Terms

Senior Management Incentive Plan, Employee Long-Term Incentive Plan, restricted stock units, Order to Cash

4 terms

Senior Management Incentive Plan financial

"under the Company's Senior Management Incentive Plan"

Employee Long-Term Incentive Plan financial

"under the Company's Employee Long-Term Incentive Plan"

restricted stock units financial

"allocated 100% to restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Order to Cash technical

"modernize its “Order to Cash” business processes"

Order to cash is the end-to-end business process that starts when a customer places an order and ends when the company receives payment. Think of it as the path from taking an order at a shop through delivery, invoicing and collecting money: faster, smoother steps mean steadier cash flow, lower risk of unpaid bills, and less working capital tied up. Investors watch it as a sign of revenue reliability and operational health.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Catherine T. Doherty retire from DGX, and what role will she take before then?

Catherine T. Doherty will retire in July 2027 and will transition to Executive Vice President effective November 1, 2026. Her responsibilities will include health systems, Quest Diagnostics’ joint venture with Corewell Health, and Project Nova.

What are Catherine T. Doherty’s DGX compensation terms?

Her annual base salary remains $650,000, and her annual incentive compensation target remains 80% of base salary under the Senior Management Incentive Plan.

What equity award did DGX approve for Catherine T. Doherty?

The award has a target value of $1,200,000, is allocated 100% to restricted stock units, and has a grant date of November 3, 2026. Its terms and conditions are substantially the same as 2026 annual long-term incentive awards granted to other senior executives.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/06/2026 - 04:31 PM Accepted by SEC EDGAR 10/06/2026 - 04:30 PM Learn about SEC filing dates

false 0001022079 false false false false false 0001022079 2026-10-06 2026-10-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): October 6, 2026

Quest Diagnostics Incorporated

(Exact Name of Registrant as Specified in Its Charter)

Delaware

(State or other jurisdiction of incorporation)

001-12215		16-1387862
(Commission File Number)		(I.R.S. Employer Identification No.)
500 Plaza Drive Secaucus, NJ		07094
(Address of principal executive offices)		(Zip Code)
(973) 520-2700
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.01 Par Value	DGX	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On October 6, 2026, Quest Diagnostics Incorporated (the “Company”) announced that Catherine T. Doherty will retire in July 2027. Until then, effective November 1, 2026, Ms. Doherty will transition to a new role as Executive Vice President with responsibilities including health systems, the Company’s joint venture with Corewell Health, and Project Nova, the Company’s multi-year project to modernize its “Order to Cash” business processes, which includes the related information technology infrastructure and underlying enabling technologies. In connection with this transition, the Company’s Compensation and Leadership Development Committee (the “Committee”) approved no change to Ms. Doherty’s annual base salary of $650,000 or annual incentive compensation under the Company's Senior Management Incentive Plan with a target amount of 80% of base salary. The Committee also approved an equity award under the Company’s Employee Long-Term Incentive Plan (“Employee Plan”) with a grant date of November 3, 2026 and a target value of $1,200,000, allocated 100% to restricted stock units. This award will be subject to terms and conditions that are substantially the same as the annual long-term incentive awards granted under the Employee Plan in 2026 to other Company senior executives.

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

October 6, 2026

QUEST DIAGNOSTICS INCORPORATED
By:	/s/ Sean D. Mersten
	Sean D. Mersten Vice President and Corporate Secretary

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL SCHEMA FILE 2.9 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.8 KB